{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:01:13Z","timestamp":1780084873451,"version":"3.54.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.bbrc.2018.02.055","type":"journal-article","created":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T05:54:48Z","timestamp":1518155688000},"page":"207-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis"],"prefix":"10.1016","volume":"497","author":[{"given":"Yuichiro","family":"Amano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuntarou","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimio","family":"Tohyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9457-3683","authenticated-orcid":false,"given":"Jun","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Isono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Yasuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Enya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Koumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nagabukuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2018.02.055_bib1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1478-3231.2008.01718.x","article-title":"Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus","volume":"29","author":"Leite","year":"2009","journal-title":"Liver Int."},{"key":"10.1016\/j.bbrc.2018.02.055_bib2","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.1464-5491.2005.01582.x","article-title":"Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults","volume":"22","author":"Jimba","year":"2005","journal-title":"Diabet. Med."},{"key":"10.1016\/j.bbrc.2018.02.055_bib3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.2040-1124.2010.00019.x","article-title":"Causes of death in Japanese diabetics: a questionnaire survey of 18,385 diabetics over a 10-year period","volume":"1","author":"Hotta","year":"2010","journal-title":"J.\u00a0Diabetes Investig."},{"key":"10.1016\/j.bbrc.2018.02.055_bib4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2036.2011.04912.x","article-title":"Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis","volume":"35","author":"Boettcher","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.bbrc.2018.02.055_bib5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/jhep.2001.21145","article-title":"Activation of retinoic X receptor and peroxisome proliferator-activated receptor-gamma inhibits nitric oxide and tumor necrosis factor-alpha production in rat Kupffer cells","volume":"33","author":"Uchimura","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2018.02.055_bib6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000168676","article-title":"Pioglitazone, a peroxisome proliferator-activated receptor gamma ligand, suppresses bleomycin-induced acute lung injury and fibrosis","volume":"77","author":"Aoki","year":"2009","journal-title":"Respiration"},{"key":"10.1016\/j.bbrc.2018.02.055_bib7","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1681\/ASN.2004040278","article-title":"Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts","volume":"16","author":"Zafiriou","year":"2005","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.bbrc.2018.02.055_bib8","first-page":"240","article-title":"Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis","volume":"75","author":"Yilmaz","year":"2012","journal-title":"Acta Gastroenterol. Belg."},{"key":"10.1016\/j.bbrc.2018.02.055_bib9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.diabres.2015.04.008","article-title":"Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes","volume":"109","author":"Kato","year":"2015","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.bbrc.2018.02.055_bib10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3892\/br.2016.569","article-title":"Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes","volume":"4","author":"Mashitani","year":"2016","journal-title":"Biomed. Rep."},{"key":"10.1016\/j.bbrc.2018.02.055_bib11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.diabres.2014.04.028","article-title":"Sitagliptin attenuates methionine\/choline-deficient diet-induced steatohepatitis","volume":"105","author":"Jung","year":"2014","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.bbrc.2018.02.055_bib12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ejphar.2013.11.030","article-title":"The novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice","volume":"723","author":"Fukuda-Tsuru","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2018.02.055_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038744","article-title":"Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity","volume":"7","author":"Kern","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2018.02.055_bib14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00795-013-0053-9","article-title":"Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis","volume":"47","author":"Klein","year":"2014","journal-title":"Med. Mol. Morphol."},{"key":"10.1016\/j.bbrc.2018.02.055_bib15","doi-asserted-by":"crossref","first-page":"29207","DOI":"10.3390\/ijms161226156","article-title":"The dipeptidyl Peptidase-4 inhibitor teneligliptin attenuates hepatic lipogenesis via AMPK activation in non-alcoholic fatty liver disease model mice","volume":"16","author":"Ideta","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2018.02.055_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13300-014-0061-3","article-title":"Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison","volume":"5","author":"Craddy","year":"2014","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.bbrc.2018.02.055_bib17","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/dom.12555","article-title":"Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double-blind, parallel-group, comparative study","volume":"17","author":"Kaku","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.bbrc.2018.02.055_bib18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/hepr.12709","article-title":"Non-alcoholic steatohepatitis-associated hepatic fibrosis and hepatocellular carcinoma in a combined mouse model of genetic modification and dietary challenge","volume":"47","author":"Amano","year":"2017","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.bbrc.2018.02.055_bib19","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1124\/jpet.108.148056","article-title":"Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob\/ob mice","volume":"329","author":"Moritoh","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbrc.2018.02.055_bib20","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/hepr.12773","article-title":"Pharmacological evaluation of pioglitazone and candesartan cilexetil in a novel mouse model of non-alcoholic steatohepatitis, modified choline-deficient, amino acid-defined diet fed low-density lipoprotein receptor knockout mice","volume":"47","author":"Tsuchiya","year":"2017","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.bbrc.2018.02.055_bib21","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ejphar.2008.11.017","article-title":"The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob\/ob mice","volume":"602","author":"Moritoh","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2018.02.055_bib22","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1476-5381.2009.00145.x","article-title":"Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db\/db mice","volume":"157","author":"Moritoh","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2018.02.055_bib23","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jhep.2008.10.027","article-title":"Prevention of steatohepatitis by pioglitazone: implication of adiponectin-dependent inhibition of SREBP-1c and inflammation","volume":"50","author":"Da Silva Morais","year":"2009","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.bbrc.2018.02.055_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158156","article-title":"Antifibrotic effects of the dual CCR2\/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis","volume":"11","author":"Lefebvre","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2018.02.055_bib25","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1053\/j.gastro.2014.06.043","article-title":"Roles for chemokines in liver disease","volume":"147","author":"Marra","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbrc.2018.02.055_bib26","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jhep.2006.02.011","article-title":"Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2","volume":"44","author":"Haukeland","year":"2006","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.bbrc.2018.02.055_bib27","doi-asserted-by":"crossref","first-page":"G1310","DOI":"10.1152\/ajpgi.00365.2011","article-title":"Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2","volume":"302","author":"Miura","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bbrc.2018.02.055_bib28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1089\/ars.2016.6953","article-title":"Gliptins suppress inflammatory macrophage activation to mitigate inflammation, fibrosis, oxidative stress, and vascular dysfunction in models of nonalcoholic steatohepatitis and liver fibrosis","volume":"28","author":"Wang","year":"2018","journal-title":"Antioxid. Redox Signal"},{"key":"10.1016\/j.bbrc.2018.02.055_bib29","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.3748\/wjg.v19.i15.2298","article-title":"Dipeptidyl peptidase-4: a key player in chronic liver disease","volume":"19","author":"Itou","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bbrc.2018.02.055_bib30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cyto.2009.08.006","article-title":"Hepatic monocyte chemoattractant protein-1 is upregulated by dietary cholesterol and contributes to liver steatosis","volume":"48","author":"Rull","year":"2009","journal-title":"Cytokine"},{"key":"10.1016\/j.bbrc.2018.02.055_bib31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/labinvest.3700489","article-title":"Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARgamma agonist pioglitazone","volume":"87","author":"Leclercq","year":"2007","journal-title":"Lab. Invest."},{"key":"10.1016\/j.bbrc.2018.02.055_bib32","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jhep.2013.06.023","article-title":"Cell-specific PPARgamma deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells","volume":"59","author":"Moran-Salvador","year":"2013","journal-title":"J.\u00a0Hepatol."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X1830278X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X1830278X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T11:24:33Z","timestamp":1757762673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X1830278X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0006291X1830278X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2018.02.055","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2018.02.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}